Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 2/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.43 |
| ▸ | AXL | P30530 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 5/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.41 |
| ▸ | LCK | P06239 | 5/20 | 0.41 |
| ▸ | FLT4 | P35916 | 5/20 | 0.41 |
| ▸ | FLT3 | P36888 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878851 | 0.85 | DYRK1A (0.59) | MAPK13MAPK12MAPK11MAPK14AAK1 | |
| SCHEMBL878747 | 0.84 | BRD4 (0.56) | AAK1DYRK1ACLK1DYRK1BPAK1 | |
| SCHEMBL857422 | 0.84 | AXL (0.61) | MAPK13AAK1DYRK1APAK1AXL | |
| SCHEMBL14620854 | 0.83 | AAK1 (0.50) | MAPK13MAPK12MAPK11MAPK14AAK1 | |
| SCHEMBL856914 | 0.81 | BRAF (0.46) | AAK1DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL878951 | 0.80 | AAK1 (0.53) | MAPK13MAPK12MAPK11MAPK14AAK1 | |
| SCHEMBL8002952 | 0.79 | AXL (0.51) | AAK1DYRK1APAK1AXLCYP3A4 | |
| SCHEMBL1516774 | 0.79 | AAK1 (0.66) | MAPK13AAK1DYRK1APAK1AXL | |
| SCHEMBL856980 | 0.78 | AAK1 (0.46) | AAK1DYRK1ACLK1DYRK2DYRK1B | |
| SCHEMBL1363678 | 0.77 | AAK1 (0.50) | MAPK13AAK1DYRK1ACLK1DYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067434-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON INC. (US) | 2011-11-29 | — | — | US | claimed |
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | PLEXXIKON INC | 2010-12-23 | — | — | US | claimed |
| CN-1925855-B | Compounds and methods for development of Ret modulators | PLEXXIKON INC | 2010-06-16 | — | — | CN | claimed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | claimed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3088400-A1 | PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC. (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| EP-2395004-B1 | Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors | PLEXXIKON INC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| EP-1696920-B1 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20130303534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-11-14 | — | — | US | disclosed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1893612-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | PLEXXIKON, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | PLEXXIKON, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | RET, GFRA3, GFRA1 | MAPK13 1284/4885MAPK12 1789/4885MAPK11 1361/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | MAPK13 50/4885MAPK12 135/4885MAPK11 68/4885 |
| US-20130303534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | MAPK13 50/4885MAPK12 135/4885MAPK11 68/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | MAPK13 50/4885MAPK12 135/4885MAPK11 68/4885 |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | RET, FGFR1, FGFR3 | MAPK13 902/4885MAPK12 1196/4885MAPK11 912/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | MAPK13 50/4885MAPK12 135/4885MAPK11 68/4885 |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | RET, GFRA1, GFRA3 | MAPK13 1764/4885MAPK12 2310/4885MAPK11 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.